MRKR
Marker Therapeutics·NASDAQ
--
--(--)
--
--(--)
MRKR fundamentals
Marker Therapeutics (MRKR) released its earnings on Nov 13, 2025: revenue was 1.23M (YoY -35.99%), beat estimates; EPS was -0.12 (YoY +53.85%), beat estimates.
Revenue / YoY
1.23M
-35.99%
EPS / YoY
-0.12
+53.85%
Report date
Nov 13, 2025
EPS
Actual | -1.4 | -1.4 | -1.6 | -1.7 | -1.6 | -1.3 | -1.5 | -1.1 | -1.2 | -1.1 | -0.8 | -0.48 | 0.29 | -0.34 | 0.44 | -0.27 | -0.25 | -0.26 | -0.41 | -0.4 | -0.25 | -0.12 | |||||||||
Forecast | -1.14 | -1.4333 | -1.45 | -1.6 | -1.45 | -1.175 | -1.275 | -1.275 | -1.2 | -1.05 | -1.3 | -1 | -0.8 | -0.9 | -0.9 | -0.25 | -0.4309 | -0.39 | -0.22 | -0.5302 | -0.3039 | -0.36 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22.81% | +2.32% | -10.34% | -6.25% | -10.34% | -10.64% | -17.65% | +13.73% | 0.00% | -4.76% | +38.46% | +52.00% | +136.25% | +62.22% | +148.89% | -8.00% | +41.98% | +33.33% | -86.36% | +24.56% | +17.74% | +66.67% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 466.79K | 0 | 0 | 0 | 0 | 0 | 1.20M | 964.32K | 790.51K | 3.95M | 3.31M | 762.66K | 257.61K | -- | 1.24M | 1.17M | 1.93M | 2.25M | 349.10K | 880.60K | 1.23M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.00M | 2.50M | 400.00K | 0 | 0 | 0 | 0 | -- | -- | 1.00M | 1.22M | 174.55K | 430.60K | 723.00K |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.57% | -68.38% | +887.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +92.60% | +84.11% | +100.00% | +104.51% | +70.53% |
Earnings Call
You can ask Aime
What is Marker Therapeutics's gross profit margin?What guidance did Marker Therapeutics's management provide for the next earnings period?What is Marker Therapeutics's latest dividend and current dividend yield?What is the revenue and EPS growth rate for Marker Therapeutics year over year?What factors drove the changes in Marker Therapeutics's revenue and profit?What does Marker Therapeutics do and what are its main business segments?What were the key takeaways from Marker Therapeutics’s earnings call?Did Marker Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
